Despite the heterogeneity of the response between patients, the triple combination of MEK, PD-L1 and Ido-1 inhibitors exerted the strongest effect with a further 15% increase in tumour cell death over the double combination of MEK and PD-L1 inhibitors. The gene discussed is MAP2K7; the disease is neoplasm.